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Background: Cocaine-associated chest pain accounts for ~40% of drug-related visits to the emergency department. It is not known whether beta-
blockers (BB) are safe in the acute management of cocaine-associated chest pain, due to fears of unopposed alpha-receptor activity.
Methods: We retrospectively identified 376 consecutive patients presenting to 2 emergency departments with chest pain and toxicology screens 
positive for cocaine. We reviewed the presence and type of BB used in the first 24 hours in relation to the primary composite endpoint: myocardial 
infarction, stroke, ventricular arrhythmia, or all-cause mortality. Characteristics of patients with and without in-hospital BB use within the first 24 
hours were compared using chi-square for categorical and t-test for continuous variables. Given the significant differences in baseline characteristics 
between patients with and without BB use, we constructed propensity scores to evaluate the independent relationship between BB use and the 
composite primary endpoint after adjustment for patient and hospital characteristics.
Results: Beta-blockers were used in 164 patients (44%), of whom 74 (45%) received z 1-selective agents and 90 (55%) received nonselective 
BBs. Patients treated with BBs were more likely to describe anginal chest pain, to have known cardiovascular risk factors, and to receive other 
therapies for coronary artery disease than patients without BB therapy. Despite these differences in clinical characteristics, BB patients had similar 
peak troponin levels (3.2±27.5 versus 1.4±12.4, p=0.443), individual adverse events, and the composite clinical outcome (15.9% versus 12.3%, 
p=0.317). Findings were similar after propensity score analysis (OR for experiencing the composite clinical endpoint was 1.37 [95% CI 0.64-2.93], 
p=0.423).
Conclusions: BB treatment in the setting of cocaine-induced chest pain may be safer than previously suggested from pathophysiologic and 
clinical studies. To help guide clinical management in the emergency setting, randomized trials comparing the use of BB versus other anti-ischemic 
therapies for patients with cocaine-related chest pain are warranted.
